Introduction: Because prior immune checkpoint inhibitor (ICI) therapy in cancer patients presenting with COVID-19 may affect outcomes, we investigated the beta-coronavirus, murine hepatitis virus (MHV)-1, in a lethal pneumonia model in the absence (Study 1) or presen...
anti-PD1 therapyBackground: Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues affdoi:10.2139/ssrn.3514597Zhang, ChaoxuFan, YiboChe, Xiaofang
研究显示细胞因子与检查点抑制剂联用能够克服耐药问题并产生协同抗肿瘤作用,但全身给药所带来的系统性毒副作用以及较短的半衰期限制了其临床应用开发。近日,药学院路慧丽团队在Molecular Therapy期刊上发表了题为:A novel anti-PD-L1/...
However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in ...
4. Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell27, 450–461. 5. Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M.J., Wallweber, H.A., Sasmal, D.K., Huang, J., Kim...
Despite promoting cell migration via intracellular IL-15, a high level of IL-15 expression in cancer cells enhances the effector function of T cells and sensitizes tumors to anti-PD-L1 therapy. Thus, our studies imply that endogenous IL-15 in cancer cells plays a pivotal role in the ...
cells, respectively [6]. Second, 65% (28/43) of melanoma patients treated with one cycle of nivolumab therapy exhibited upregulated PD-L1 expression as assessed by RNA-sequencing [7]. In cervical cancer lesions that are irradiated, this may also occur....
PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: The Cochrane Controlled Trial Register, Embase, Medline, and the Science Citation Index...
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. Epub 2017 Aug 23.Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia (2018) 32:230-3. doi: 10.1038/...
Anti-PD-1/PD-L1 therapy in MSI-H/dMMR advanced CRC was associated with improved survival. Anti PD-1/PD-L1 combined with antiangiogenic drugs, targeted agents, or chemotherapy might be effective in MSS mCRC. Immunotherapy was effective for the BRAF mutant and KRAS/NRAS(RAS) mutant CRC. Lo...